WallStreetZenWallStreetZen

Sectors & IndustriesHealthcareDiagnostics & Research
Best Diagnostic & Research Stocks to Buy Now (2024)
Top diagnostic & research stocks in 2024 ranked by overall Zen Score. See the best diagnostic & research stocks to buy now, according to analyst forecasts for the diagnostics & research industry.

Industry: Diagnostics & Research
Ticker
Company
Forecast Score
Market Cap
Price
Price Target
Upside/Downside
Top Analysts Upside/Downside
Consensus
Top Analysts Consensus
Analysts
Top Analysts
Fore. Revenue Growth
Fore. Earnings Growth
Forecast ROE
Forecast ROA
ICLR
ICON PLC
$26.02B$314.72$344.389.42%Strong Buy86.04%31.77%N/AN/A
STRR
STAR EQUITY HOLDINGS INC
$13.95M$0.88N/AN/AN/AN/AN/AN/AN/AN/A
FONR
FONAR CORP
$102.27M$15.24N/AN/AN/AN/AN/AN/AN/AN/A
TMO
THERMO FISHER SCIENTIFIC INC
$227.24B$595.30$628.205.53%Buy104.16%56.87%N/AN/A
IDXX
IDEXX LABORATORIES INC
$44.88B$543.45$594.209.34%Strong Buy58.70%7.44%N/AN/A
CRL
CHARLES RIVER LABORATORIES INTERNATIONAL INC
$11.42B$221.61$267.5720.74%Buy75.14%56.30%N/AN/A
ENZ
ENZO BIOCHEM INC
$55.84M$1.09N/AN/AN/AN/AN/AN/AN/AN/A
DGX
QUEST DIAGNOSTICS INC
$16.03B$144.34$148.753.06%Buy82.89%14.83%N/AN/A
MEDP
MEDPACE HOLDINGS INC
$12.19B$393.30$448.6014.06%Strong Buy512.68%0.10%N/AN/A
SHC
SOTERA HEALTH CO
$3.20B$11.29$16.3845.04%Strong Buy44.69%245.65%N/AN/A
NEOG
NEOGEN CORP
$2.93B$13.54$17.0025.55%Hold10.76%526.68%6.20%4.25%
A
AGILENT TECHNOLOGIES INC
$45.20B$154.23$139.67-9.44%Buy123.34%35.95%N/AN/A
LAB
STANDARD BIOTOOLS INC
$956.40M$2.57$3.3831.32%Strong Buy227.64%N/AN/AN/A
QGEN
QIAGEN NV
$10.23B$45.69$50.6610.89%Buy55.09%26.17%N/AN/A
DHR
DANAHER CORP
$196.87B$265.80$278.304.70%Strong Buy107.35%57.06%N/AN/A
FLGT
FULGENT GENETICS INC
$661.63M$22.11$30.0035.69%Hold26.26%N/AN/AN/A
SERA
SERA PROGNOSTICS INC
$269.72M$8.26N/AN/AN/AN/A69.90%N/AN/AN/A
CSTL
CASTLE BIOSCIENCES INC
$669.20M$24.24$31.0027.89%Strong Buy44.04%N/AN/AN/A
EXAS
EXACT SCIENCES CORP
$9.30B$50.38$85.2069.11%Strong Buy512.57%N/AN/AN/A
NTRA
NATERA INC
$13.07B$106.46$109.002.39%Strong Buy1118.69%N/AN/AN/A
PRE
PRENETICS GLOBAL LTD
$70.84M$5.80$9.0055.07%Strong Buy1N/AN/AN/AN/A
RVTY
REVVITY INC
$13.60B$110.23$118.897.86%Buy94.93%221.37%N/AN/A
CHEK
CHECK-CAP LTD
$12.78M$2.19N/AN/AN/AN/AN/AN/AN/AN/A
OLK
OLINK HOLDING AB (PUBL)
$2.98B$23.95$26.008.56%Hold223.69%N/AN/AN/A
WAT
WATERS CORP
$21.11B$355.95$322.83-9.30%Hold64.14%36.24%N/AN/A
LH
LABCORP HOLDINGS INC
$17.75B$210.59$242.4015.11%Buy55.13%113.65%N/AN/A
NEO
NEOGENOMICS INC
$1.89B$14.80$20.4338.03%Strong Buy78.77%N/AN/AN/A
IQV
IQVIA HOLDINGS INC
$42.12B$231.18$269.0016.36%Strong Buy85.53%30.00%N/AN/A
DRIO
DARIOHEALTH CORP
$56.85M$1.90$4.00110.53%Strong Buy138.44%N/AN/AN/A
TWST
TWIST BIOSCIENCE CORP
$2.74B$47.01$45.60-3.00%Strong Buy514.23%N/AN/AN/A
PRPO
PRECIPIO INC
$9.24M$6.29N/AN/AN/AN/AN/AN/AN/AN/A
MTD
METTLER TOLEDO INTERNATIONAL INC
$32.52B$1,522.75$1.34k-11.84%Hold43.63%30.33%N/AN/A
BNR
BURNING ROCK BIOTECH LTD
$85.03M$8.30N/AN/AN/AN/AN/AN/A-732.54%-541.24%
ACRS
ACLARIS THERAPEUTICS INC
$84.81M$1.19$5.00320.17%Buy2-39.66%N/AN/AN/A
RDNT
RADNET INC
$4.24B$57.45$57.25-0.35%Strong Buy46.88%48.73%N/AN/A
PSNL
PERSONALIS INC
$72.71M$1.40$3.75167.86%Strong Buy211.51%N/AN/AN/A
CDNA
CAREDX INC
$807.30M$15.50$17.2511.29%Strong Buy43.22%N/AN/AN/A
STIM
NEURONETICS INC
$78.29M$2.61$8.00206.51%Strong Buy19.62%N/AN/AN/A
ME
23ANDME HOLDING CO
$283.47M$0.59$0.47-19.93%Hold16.26%N/AN/AN/A
GH
GUARDANT HEALTH INC
$3.10B$25.36$32.2026.97%Strong Buy517.07%N/AN/AN/A
XWEL
XWELL INC
$7.28M$1.74N/AN/AN/AN/AN/AN/AN/AN/A
XGN
EXAGEN INC
$32.66M$1.88$7.00272.34%Strong Buy1-0.51%N/AN/AN/A
OCX
ONCOCYTE CORP
$39.16M$2.93$4.4250.75%Buy3N/AN/A322.93%52.73%
MYGN
MYRIAD GENETICS INC
$2.29B$25.29$27.257.75%Strong Buy47.86%N/AN/AN/A
DMTK
DERMTECH INC
$17.45M$0.50$1.38175.95%Buy326.40%N/A-152.99%-59.42%
PRPH
PROPHASE LABS INC
$95.97M$5.03$11.00118.69%Buy191.36%N/AN/AN/A
NDRA
ENDRA LIFE SCIENCES INC
$3.39M$0.31N/AN/AN/AN/AN/AN/AN/AN/A
AWH
ASPIRA WOMEN's HEALTH INC
$33.12M$2.66$3.3024.06%Hold119.01%N/AN/AN/A
VNRX
VOLITIONRX LTD
$63.77M$0.77$3.50354.55%Strong Buy2N/AN/AN/AN/A
MDXH
MDXHEALTH SA
$7.86M$2.88$7.50160.42%Strong Buy211.69%N/AN/AN/A
GENE
GENETIC TECHNOLOGIES LTD
$526.30k$2.28N/AN/AN/AN/AN/AN/AN/AN/A
NOTV
INOTIV INC
$50.12M$1.93$5.25172.02%Hold3-0.72%N/AN/AN/A
MYNZ
MAINZ BIOMED NV
$14.39M$0.68$3.00341.18%Buy1N/AN/AN/AN/A
BIAF
BIOAFFINITY TECHNOLOGIES INC
$26.35M$2.26N/AN/AN/AN/AN/AN/AN/AN/A
ILMN
ILLUMINA INC
$17.69B$111.07$150.2535.28%Hold84.91%N/AN/AN/A
OPK
OPKO HEALTH INC
$920.03M$1.32$3.17139.92%Strong Buy32.63%N/AN/AN/A
APDN
APPLIED DNA SCIENCES INC
$2.47M$2.51$40.001,493.63%Buy112.37%N/AN/AN/A
PMD
PSYCHEMEDICS CORP
$14.98M$2.58N/AN/AN/AN/AN/AN/AN/AN/A
TRIB
TRINITY BIOTECH PLC
$12.11M$1.58N/AN/AN/AN/A17.89%N/AN/AN/A
BDSX
BIODESIX INC
$180.63M$1.58$3.15100.00%Strong Buy220.60%N/AN/AN/A
MMA
ALTA GLOBAL GROUP LTD
N/A$4.54N/AN/AN/AN/AN/AN/AN/AN/A
ISPC
ISPECIMEN INC
$2.40M$0.24N/AN/AN/AN/AN/AN/AN/AN/A
TTOO
T2 BIOSYSTEMS INC
$49.59M$5.64$3.00-46.81%Hold1N/AN/AN/AN/A
CNTG
CENTOGENE NV
$10.21M$0.37N/AN/AN/AN/AN/AN/AN/AN/A

Diagnostic & Research Stocks FAQ

What are the best diagnostic & research stocks to buy right now in May 2024?

According to Zen Score, the 3 best diagnostic & research stocks to buy right now are:

1. Icon (NASDAQ:ICLR)


Icon (NASDAQ:ICLR) is the top diagnostic & research stock with a Zen Score of 47, which is 21 points higher than the diagnostic & research industry average of 26. It passed 15 out of 33 due diligence checks and has strong fundamentals. Icon has seen its stock return 49.4% over the past year, overperforming other diagnostic & research stocks by 38 percentage points.

Icon has an average 1 year price target of $344.38, an upside of 9.42% from Icon's current stock price of $314.72.

Icon stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 8 analysts covering Icon, 75% have issued a Strong Buy rating, 25% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Star Equity Holdings (NASDAQ:STRR)


Star Equity Holdings (NASDAQ:STRR) is the second best diagnostic & research stock with a Zen Score of 46, which is 20 points higher than the diagnostic & research industry average of 26. It passed 18 out of 38 due diligence checks and has strong fundamentals. Star Equity Holdings has seen its stock return 10% over the past year, underperforming other diagnostic & research stocks by -1 percentage points.

3. Fonar (NASDAQ:FONR)


Fonar (NASDAQ:FONR) is the third best diagnostic & research stock with a Zen Score of 43, which is 17 points higher than the diagnostic & research industry average of 26. It passed 13 out of 33 due diligence checks and has strong fundamentals. Fonar has seen its stock lose -9.98% over the past year, underperforming other diagnostic & research stocks by -21 percentage points.

What are the diagnostic & research stocks with highest dividends?

Out of 7 diagnostic & research stocks that have issued dividends in the past year, the 3 diagnostic & research stocks with the highest dividend yields are:

1. Qiagen Nv (NYSE:QGEN)


Qiagen Nv (NYSE:QGEN) has an annual dividend yield of 2.8%, which is 2 percentage points higher than the diagnostic & research industry average of 1.25%.

Qiagen Nv's dividend payout ratio of 87.2% indicates that its dividend yield is sustainable for the long-term.

2. Quest Diagnostics (NYSE:DGX)


Quest Diagnostics (NYSE:DGX) has an annual dividend yield of 2%, which is 1 percentage points higher than the diagnostic & research industry average of 1.25%. Quest Diagnostics's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Quest Diagnostics's dividend has shown consistent growth over the last 10 years.

Quest Diagnostics's dividend payout ratio of 38.2% indicates that its dividend yield is sustainable for the long-term.

3. Labcorp Holdings (NYSE:LH)


Labcorp Holdings (NYSE:LH) has an annual dividend yield of 1.03%, which is the same as the diagnostic & research industry average of 1.25%. Labcorp Holdings's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Labcorp Holdings's dividend has not shown consistent growth over the last 10 years.

Labcorp Holdings's dividend payout ratio of 56.5% indicates that its dividend yield is sustainable for the long-term.

Why are diagnostic & research stocks down?

Diagnostic & research stocks were down -0.44% in the last day, and up 1.56% over the last week.

We couldn't find a catalyst for why diagnostic & research stocks are down.

What are the most undervalued diagnostic & research stocks?

Based on WallStreetZen's Valuation Score, the 3 most undervalued diagnostic & research stocks right now are:

1. Star Equity Holdings (NASDAQ:STRR)


Star Equity Holdings (NASDAQ:STRR) is the most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Star Equity Holdings has a valuation score of 71, which is 53 points higher than the diagnostic & research industry average of 18. It passed 5 out of 7 valuation due diligence checks.

Star Equity Holdings's stock has gained 10% in the past year. It has underperformed other stocks in the diagnostic & research industry by -1 percentage points.

2. Enzo Biochem (NYSE:ENZ)


Enzo Biochem (NYSE:ENZ) is the second most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Enzo Biochem has a valuation score of 71, which is 53 points higher than the diagnostic & research industry average of 18. It passed 5 out of 7 valuation due diligence checks.

Enzo Biochem's stock has dropped -52.81% in the past year. It has underperformed other stocks in the diagnostic & research industry by -64 percentage points.

3. Fonar (NASDAQ:FONR)


Fonar (NASDAQ:FONR) is the third most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Fonar has a valuation score of 71, which is 53 points higher than the diagnostic & research industry average of 18. It passed 5 out of 7 valuation due diligence checks.

Fonar's stock has dropped -9.98% in the past year. It has underperformed other stocks in the diagnostic & research industry by -21 percentage points.

Are diagnostic & research stocks a good buy now?

52.08% of diagnostic & research stocks rated by analysts are a strong buy right now. On average, analysts expect diagnostic & research stocks to rise by 5.02% over the next year.

What is the average p/e ratio of the diagnostics & research industry?

The average P/E ratio of the diagnostics & research industry is 38.96x.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.